Our proprietary delivery architectures are designed to be modular — adaptable to diverse payload classes, administration routes, and therapeutic contexts without reengineering from scratch.
Precision intracellular delivery
Our proprietary ionizable lipid formulation achieves >87% encapsulation efficiency across mRNA, siRNA, and small molecule payloads. The PEGylation surface chemistry extends circulation half-life to 18–24 hours while reducing immunogenic clearance by 63%.
Sustained zero-order kinetics
PLGA-based microsphere architecture engineered for programmable release profiles spanning 14–180 days. The hydrolytic degradation pathway eliminates retrieval procedures, and pH-responsive shell layers enable targeted gastrointestinal delivery.
Tumor-selective payload deposition
Site-specific cysteine conjugation technology with a drug-to-antibody ratio of 3.8 ± 0.4. The cleavable valine-citrulline linker releases cytotoxic payload exclusively in lysosomal pH environments, limiting off-target exposure to <0.3% of administered dose.
| Program | Indication | Platform | Phase | Progress | Partner | Next Milestone |
|---|---|---|---|---|---|---|
AVD-201 mRNA-encoded IL-12 immunotherapy | Pancreatic Adenocarcinoma | LNP-X4 | Phase 2 | 68% | Independent | Q3 2026 interim data readout |
AVD-114 CNS siRNA knockdown of HTT | Huntington's Disease | PMR-7 | Phase 1 | 42% | Beacon Neuroscience | Dose-escalation cohort 3 active |
AVD-389 Anti-TROP2 MMAE conjugate | Triple-Negative Breast Cancer | ADC-Link | Phase 3 | 91% | Meridian Oncology | NDA submission anticipated Q1 2027 |
AVD-077 Intravitreal sustained-release anti-VEGF | Wet AMD | PMR-7 | Phase 2 | 55% | Prism Ophthalmics | Month-6 endpoint analysis underway |
AVD-512 SMN2 splicing modulator mRNA | Spinal Muscular Atrophy (Type 3) | LNP-X4 | Preclinical | 20% | Internal | IND-enabling studies FY2025 |
AVD-441 Anti-CD33 calicheamicin conjugate | Acute Myeloid Leukemia | ADC-Link | Phase 1 | 35% | Harborview Hematology | MTD determination Q4 2025 |
The pharmacological activity of a drug is only as good as its ability to reach the target tissue at therapeutic concentration. We believe drug delivery engineering is not a formulation afterthought — it is the central design variable that determines clinical success.
Our platforms are built around three first principles: selectivity (getting the payload to the right cell type), kinetics (releasing it at the right rate), and scalability (manufacturing at GMP standards from early IND through commercial supply).
Former VP Drug Delivery, Roche Pharma; PhD Pharmaceutical Sciences, MIT; 24 years industry experience
Pioneer of ionizable lipid chemistry; 47 peer-reviewed publications; ex-Arrowhead Research
Former oncology medical lead, AstraZeneca; board-certified oncologist; 18 INDs filed
Previously CFO at Alector Therapeutics; led Series B–D financings totaling $680M; Wharton MBA
Whether you have a promising molecule that needs the right delivery architecture, or a clinical challenge that our platforms might address, we want to hear from you. Aveva engages in licensing, co-development, and full-program partnerships.